Table 1.
Clinical trials using hESC- and hiPSC-derived products (modified by Trounson and McDonald [107]).
| Trial sponsor (location) | Targeted disease | Cell type | Phase | Clinical trial ID | Trial status | Reports |
|---|---|---|---|---|---|---|
| Geron Corp. (USA) | Spinal cord injury | hES-derived OPCs | I | NCT01217008 | Complete | Not provided |
|
| ||||||
| Asterias Biotherapeutics (USA) | Spinal cord injury | hES-derived OPCs | I/IIa | NCT02302157 | On-going | Not available yet |
|
| ||||||
| Ocata Therapeutics (USA) | Stargardt's macular dystrophy | hES-derived RPE | I/II | NCT01345006 | On-going | [108, 109] |
| Macular degeneration | hES-derived RPE | I/II | NCT01344993 | On-going | ||
| Myopic macular degeneration | hES-derived RPE | I/II | NCT02122159 | Not open yet | — | |
|
| ||||||
| Pfizer (UK) | Macular degeneration | hES-derived RPE | I | NCT01691261 | On-going | Not available yet |
|
| ||||||
| Cell Cure Neurosciences Ltd. (Israel) | Macular degeneration | hES-derived RPE | I/IIa | NCT02286089 | On-going | Not available yet |
|
| ||||||
| Chabiotech Ltd. (South Korea) | Macular degeneration | hES-derived RPEs | I/IIa | NCT01674829 | On-going | [110] |
|
| ||||||
| ViaCyte (USA) | Type-1 diabetes mellitus | hES-derived PP | I/II | NCT02239354 | On-going | Not available yet |
|
| ||||||
| Assistance Publique-Hôpitaux de Paris (France) |
Severe heart failure | hES-derived CD15 + Isl-1 + progenitors | I | NCT02057900 | On-going | Not available yet |
|
| ||||||
| International Stem Cell Corp. (Australia) | Parkinson disease | hpESC-derived NSC | I | NCT02452723 | Not open yet | — |
|
| ||||||
| RIKEN Center for Developmental Biology | Macular degeneration | iPSC-derived RPEs | I | — | On-going | Not available yet |